Artificial Intelligence Predicts Risk of Progression Common Blinding Eye Disease

Artificial Intelligence Predicts Risk of Progression Common Blinding Eye Disease


A new artificial intelligence (AI) algorithm developed by researchers can rapidly and accurately detect age-related macular degeneration (AMD), a leading cause of vision loss.

In AMD the central area of the retina called the macula—the location of central vision—deteriorates, leading to blurry vision that can drastically worsen over time. The study, published in Translational Vision Science and Technology, is the first toshow that AI technology may help doctors to predict the risk of AMD progression and severity, which can prompt patients to get earlier medical treatment and save their eyesight.
 
“We are excited to have built a deep-learning form of AI that can be trained to match the performance of a human expert to accurately diagnose AMD grade and stage based on scanning retinal photographs, without using other information. This is an important step in identifying those at risk for late-stage AMD and may allow them to get quick referral to an eye specialist for timely, preventive treatment,” explains the senior author.

“This algorithm can easily be applied in the ophthalmology telemedicine landscape as the practice of medicine transforms under the impact of the COVID pandemic to embrace ‘medicine at a distance.’  For example, our large ambulatory facilities can strategically place teleophthalmology kiosks with inexpensive cameras that take these retinal images to screen underserved populations for AMD. The AI algorithm would instantly generate results, so patients get immediate diagnosis, and if they need additional care, they could have a same-day follow-up at a nearby ophthalmic center. This may become an important and cost-effective tool for high-risk or low-income groups who may not have direct or frequent access to eye screening, as early detection is critical to preventing AMD. This will not only aid in quick diagnosis, but help to close gaps in health disparities.”

Researchers developed deep-learning AI screening and prediction models using data from the Age Related Eye Disease Study, a large study of AMD over 15 years sponsored by the National Institutes of Health. Patients between 55 and 80 years old were grouped into categories for normal, early, intermediate, and advanced or late AMD.

For screening, the investigators took 116,875 color fundus photos (images that capture the interior surface of the eye) from 4,139 participants and trained the algorithm to classify them as “no,” “early,” “intermediate,” or “advanced” AMD along a 12-level severity scale to match the findings of human experts. Overall their algorithm achieved 98 percent accuracy when matching decisions of experts.

The researchers then took the severity scores and combined them with the patients’ sociodemographic clinical data (including age, gender, and medical history, such as cardiac illness or diabetes, diet, and tobacco use) and other imaging data in a second algorithm to predict AMD progression, specifically risk for progression to late AMD within one or two years. They trained and validated the predictive learning model on 923 participants who had AMD progression within two years, 901 patients who had progression within one year, and 2,840 patients who did not progress within two years.

The AI model further refined the risk of progression to late AMD so that researchers were able to predict the exact type of progression of late AMD—either dry or wet. Dry AMD develops more slowly; layers of the macula become progressively thin and lose function. In wet AMD, which is more rapid, abnormal blood vessels form behind the retina and leak.  

“The prediction program will produce a report that can help eye doctors counsel AMD patients on their risk for progression based on their retinal photographs and other lifestyle (diet and smoking) and demographic variables: age, gender, and medical history. The ophthalmologist can then recommend changes in modifiable factors in consultation with family and the primary care physician, and patients at high risk can be followed up with sooner,” explains the author.
 
 “The proposed noninvasive technology thus proceeds in two steps:  we first screen high volumes of patients in the community to find the at-risk patients with intermediate and advanced AMD forreferral to an ophthalmologist, and second, we help the eye doctor manage these patients by predicting if they will develop late AMD in one to two years. This can allow screening to take place more efficiently and cost-effectively in primary care clinics, with detection of a much smaller at-risk group for referral to specialty care.”

 https://www.mountsinai.org/about/newsroom/2020/artificial-intelligence-algorithm-can-rapidly-detect-severity-of-common-blinding-eye-disease-pr

https://tvst.arvojournals.org/article.aspx?articleid=2765234

http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fartificial-intelligence_2&filter=22

Edited

Rating

Unrated
Rating: